1. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.
- Author
-
Avramova BE, Yordanova MN, Konstantinov DN, and Bobev DG
- Subjects
- Adolescent, Antigens, CD34 metabolism, Benzylamines, Blood Cell Count, Child, Cyclams, Hematopoietic Stem Cell Mobilization adverse effects, Hematopoietic Stem Cell Mobilization methods, Heterocyclic Compounds adverse effects, Humans, Leukapheresis methods, Male, Transplantation, Autologous, Treatment Outcome, Granulocyte Colony-Stimulating Factor administration & dosage, Heterocyclic Compounds administration & dosage, Neoplasms therapy, Peripheral Blood Stem Cell Transplantation methods
- Abstract
This paper describes the successful mobilization of peripheral blood stem cells for autologous transplantation in three children with malignant diseases by using plerixafor (Mozobil; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor (G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circulating CD34+ cells after plerixafor treatment as compared with the baseline level was observed. An optimal CD34+ cell count for transplantation with one or two leukapheresis sessions was achieved. Mobilization using plerixafor was found to be safe with no adverse events. Therefore, the combination of G-CSF and plerixafor in children results in effective increases in peripheral CD34+ cell counts and reduces the risk of mobilization failure.
- Published
- 2011
- Full Text
- View/download PDF